Autoantibodies to plasminogen and tissue plasminogen activator in women with recurrent pregnancy loss

Clinical and Experimental Immunology

Volumn 149, Issue 1, 2007, Pages 31-39

  Bu, C ^a   Zhang, C ^a   Li, Z ^a   Gao, L ^a   Xie, Z ^a   Cai, G ^a  

^a TSINGHUA UNIVERSITY   (China)

Author keywords

APS; Fibrinolysis; Plasminogen; Recurrent pregnancy loss; t PA

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PLASMINOGEN ACTIVATOR ANTIBODY; TISSUE PLASMINOGEN ACTIVATOR ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; FISHER EXACT TEST; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENT ABORTION;

ABORTION, HABITUAL; ADULT; AUTOANTIBODIES; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; HUMANS; IMMUNOGLOBULIN G; PLASMINOGEN; PREGNANCY; SEVERITY OF ILLNESS INDEX; TISSUE PLASMINOGEN ACTIVATOR; UMBILICAL VEINS;

EID: 34250182786     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2007.03382.x     Document Type: Article

References (33)

1. de Groot PG, Derksen RH. Pathophysiology of the antiphospholipid syndrome. J Thromb Haemost 2005 3 : 1854 60.
2. Vinatier D, Dufour P, Cosson M, Houpeau JL. Antiphospholipid syndrome and recurrent miscarriages. Eur J Obstet Gynecol Reprod Biol 2001 96 : 37 50.
3. Branch DW, Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet Gynecol 2003 101 : 1333 44.
4. Marai I, Zandman-Goddard G, Shoenfeld Y. The systemic nature of the antiphospholipid syndrome. Scand J Rheumatol 2004 33 : 365 72.
5. Caruso A, De Carolis S, Di Simone N. Antiphospholipid antibodies in obstetrics: new complexities and sites of action. Hum Reprod Update 1999 5 : 267 76.
6. Mackworth-Young CG. Antiphospholipid syndrome: multiple mechanisms. Clin Exp Immunol 2004 136 : 393 401.
7. Esmon CT. Regulation of blood coagulation. Biochim Biophys Acta 2000 1477 : 349 60.
8. Yang CD, Hwang KK, Yan W et al. Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. J Immunol 2004 172 : 5765 73.
9. Yasuda S, Atsumi T, Ieko M, Koike T. Beta2-glycoprotein 1, anti-beta2-glycoprotein 1, and fibrinolysis. Thromb Res 2004 114 : 461 5.
10. Ieko M, Sawada KI, Koike T et al. The putative mechanism of thrombosis in antiphospholipid syndrome: impairment of the protein C and the fibrinolytic systems by monoclonal anticardiolipin antibodies. Semin Thromb Hemost 1999 25 : 503 7.
11. Ieko M, Ichikawa K, Atsumi T et al. Effects of beta2-glycoprotein 1 and monoclonal anticardiolipin antibodies on extrinsic fibrinolysis. Semin Thromb Hemost 2000 26 : 85 90.
12. Stefanescu M, Szegli G, Cremer L et al. The presence and significance of some anti-enzyme antibodies (anti-plasminogen, anti-trypsin, anti-phospholipase C) in rheumatoid arthritis (RA) and reactive arthritis (rA). Arch Roum Pathol Exp Microbiol 1989 48 : 47 53.
13. Gonzalez-Gronow M, Cuchacovich M, Grigg DM, Pizzo SV. Analysis of autoantibodies to plasminogen in the serum of patients with rheumatoid arthritis. J Mol Med 1996 74 : 463 9.
14. Kozmin LD, Shirokova IE, Lisitsina TA et al. Anti-plasminogen autoantibodies from plasma of patients with systemic lupus erythematosus having anti-phospholipid antibody syndrome: isolation and some immunochemical properties. Biochemistry (Mosc) 2003 68 : 339 45.
15. Simmelink MJ, De Groot PG, Derksen RH. A study on associations between antiprothrombin antibodies, antiplasminogen antibodies and thrombosis. J Thromb Haemost 2003 1 : 735 9.
16. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005 129 : 307 21.
17. Cugno M, Dominguez M, Cabibbe M et al. Antibodies to tissue-type plasminogen activator in plasma from patients with primary antiphospholipid syndrome. Br J Haematol 2000 108 : 871 5.
18. Cugno M, Cabibbe M, Galli M et al. Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients. Blood 2004 103 : 2121 6.
19. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997 40 : 1725.
20. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006 4 : 295 306.
21. Brandt JT, Triplett DA Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995 74 : 1185 90.
22. Cai G, Guo Y, Shi J. Purification of apolipoprotein H by polyethylene glycol precipitation. Protein Expr Purif 1996 8 : 341 6.
23. Reber G, Tincani A, Sanmarco M, de Moerloose P, Boffa MC. Proposals for the measurement of anti-beta2-glycoprotein 1 antibodies. J Thromb Haemost 2004 2 : 1860 2.
24. Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem 1994 269 : 21198 203.
25. Hajjar KA, Harpel PC, Jaffe EA, Nachman RL. Binding of plasminogen to cultured human endothelial cells. J Biol Chem 1986 261 : 11656 62.
26. Branch DW, Dudley DJ, Mitchell MD et al. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 1990 163 : 210 16.
27. Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci USA 1991 88 : 3069 73.
28. Meroni PL, di Simone N, Testoni C, D'Asta M, Acaia B, Caruso A. Antiphospholipid antibodies as cause of pregnancy loss. Lupus 2004 13 : 649 52.
29. Saibeni S, Ciscato C, Vecchi M et al. Antibodies to tissue-type plasminogen activator (t-PA) in patients with inflammatory bowel disease. high prevalence, interactions with functional domains of t-PA and possible implications in thrombosis. J Thromb Haemost 2006 4 : 1510 16.
30. Juhan-Vague I, Valadier J, Alessi MC et al. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 1987 57 : 67 72.
31. Gris JC, Neveu S, Mares P, Biron C, Hedon B, Schved JF. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology. J Lab Clin Med 1993 122 : 606 15.
32. Hu ZY, Liu YX, Liu K et al. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta. J Anat 1999 194 : 183 95.
33. Gris JC, Perneger TV, Quere I et al. Antiphospholipid/antiprotein antibodies, hemostasis-related autoantibodies, and plasma homocysteine as risk factors for a first early pregnancy loss: a matched case-control study. Blood 2003 102 : 3504 13.